Rocket Lab's Valuation Puzzle: Record Contracts Can't Mask the Iridium Financing Question
Published on 08/01/2026 at 14:03 | Redaktion boerse-global.de
There aren't many companies that can land a near-billion-dollar government contract, ink another multi-launch deal with a repeat customer, and still watch their stock get cut down by more than a third in a single month. Rocket Lab is managing exactly that balancing act — and the market's verdict on its biggest strategic bet yet is growing harder to ignore.
The numbers tell a story of operational momentum colliding with balance-sheet anxiety. Revenue for the first quarter climbed roughly 63 percent year over year to a record $200.3 million, while the backlog swelled to $2.2 billion — a gain of about 20 percent in just three months. Management has guided to another record quarter, projecting second-quarter sales between $225 million and $240 million. The debut flight of the larger Neutron rocket remains on track for later this year.
None of that has been enough to steady the share price. The stock closed the final session of July with a modest 0.36 percent uptick to €56.30, but the monthly damage stands at a bruising 36.02 percent decline. Year to date, the equity is down 8.46 percent — a figure that underscores just how much of the selling has been compressed into recent weeks.
A Deal That Changed the Conversation
The catalyst for the sell-off isn't hard to pinpoint. Late June brought news that Rocket Lab would acquire satellite operator Iridium Communications in a deal valued at roughly $8 billion. Iridium shareholders are set to receive $54 per share — half in cash, half in Rocket Lab stock via an exchange ratio that begins at a $67.50 share price.
Should investors sell immediately? Or is it worth buying Rocket Lab?
That lower bound is now the crux of the problem. Rocket Lab's shares are trading beneath it, turning the equity component of the financing into a live point of contention. Investors are left to puzzle over how the transaction ultimately gets priced, and whether the company's currency has lost some of its purchasing power.
The cash-flow picture adds another layer of concern. Rocket Lab burned through $321.8 million in free cash flow during fiscal 2025, and the first quarter alone saw the company raise an additional $450 million through an at-the-market equity program. That fresh capital keeps the lights on, but it also signals just how hungry the business is for liquidity as it juggles the Iridium acquisition alongside its Neutron development program.
Piper Sandler captured the prevailing caution when it initiated coverage with a Neutral rating and an $83 price target, pointing to the valuation. The price-to-sales ratio sits at 54 — a multiple that looks rich even by growth-stock standards.
The Order Book Keeps Growing Anyway
For all the financing worries, the commercial engine hasn't stalled. On July 30, Rocket Lab announced another multi-launch agreement with Japanese satellite operator iQPS — three dedicated Electron missions scheduled to begin in late 2027. That brings iQPS's total booked launches to 18, and marks the third order of this scale from the company within a year.
The significance goes beyond the individual contract. Constellation operators returning again and again gives Rocket Lab a degree of revenue visibility that the current share price simply doesn't reflect. It's the kind of recurring demand that underpins the bull case.
The government side has been busy too. This week, Rocket Lab was named a participant in a US Space Force indefinite-delivery contract running through 2032 with a ceiling of $981 million, covering space testing and training missions. That follows a separate record award from the Space Force: $266 million for twelve suborbital missions from the Kodiak launch site in Alaska, with options for six more through 2028 — the largest contract of its kind in company history.
Analysts Versus the Tape
The gap between Wall Street's targets and the market's pricing has become one of the widest of the season. The average analyst price target sits near €99.75, implying upside of roughly 77.2 percent from the Friday close. KGI Securities upgraded the stock to Outperform in late July with a €107 target, while Bank of America reaffirmed its Buy rating at €115. The broader consensus clusters around €106.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
That kind of divergence typically resolves in one direction or the other, and the market cap of €35.11 billion suggests investors are already pricing in a more skeptical view of the Iridium deal's execution risk.
What August 10 Could Settle
The next major checkpoint arrives on Monday, August 10, 2026, when Rocket Lab reports second-quarter results after the US market close. It will be the first comprehensive earnings report since the Iridium announcement, and investors will be parsing it for three things: revenue momentum, the cash position, and progress on the Neutron timeline.
Technically, the stock looks stretched to the downside. The relative strength index sits at 36.7, approaching the oversold threshold of 30, while the share price trades 16.43 percent below its 200-day moving average — a measure of how far the equity has drifted from its longer-term trend.
The company's transformation from a pure launch provider into a vertically integrated space infrastructure player is real. The Space Force framework agreement and the Iridium bid both point in that direction, toward higher-margin satellite services and away from the capital-intensive, risk-laden launch business. Whether the market is willing to underwrite that transition at current valuations is a different question entirely. The earnings call on August 10 will offer the first real test of whether the operational strength can finally outweigh the financing concerns — or whether the disconnect between the record backlog and the beaten-down chart has further to run.
Ad
Rocket Lab Stock: New Analysis - 1 August
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
